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Abstract
Resident alveolar macrophages (AMs) suppress allergic inflammation in murine 
asthma models. Previously we reported that resident AMs can blunt inflammatory 
signaling in alveolar epithelial cells (ECs) by transcellular delivery of suppressor of 
cytokine signaling 3 (SOCS3) within extracellular vesicles (EVs). Here we examined 
the role of vesicular SOCS3 secretion as a mechanism by which AMs restrain al-
lergic inflammatory responses in airway ECs. Bronchoalveolar lavage fluid (BALF) 
levels of SOCS3 were reduced in asthmatics and in allergen-challenged mice. Ex 
vivo SOCS3 secretion was reduced in AMs from challenged mice and this defect was 
mimicked by exposing normal AMs to cytokines associated with allergic inflamma-
tion. Both AM-derived EVs and synthetic SOCS3 liposomes inhibited the activation 
of STAT3 and STAT6 as well as cytokine gene expression in ECs challenged with 
IL-4/IL-13 and house dust mite (HDM) extract. This suppressive effect of EVs was 
lost when they were obtained from AMs exposed to allergic inflammation-associ-
ated cytokines. Finally, inflammatory cell recruitment and cytokine generation in the 
lungs of OVA-challenged mice were attenuated by intrapulmonary pretreatment with 
SOCS3 liposomes. Overall, AM secretion of SOCS3 within EVs serves as a brake 
on airway EC responses during allergic inflammation, but  is impaired in asthma. 
Synthetic liposomes encapsulating SOCS3 can rescue this defect and may serve as a 
framework for novel therapeutic approaches targeting airway inflammation.
K E Y W O R D S
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1 |  INTRODUCTION
Carrying out the lung’s principal physiologic function of gas 
exchange in the face of a continuous barrage of inhaled aller-
gens, toxins, and microbes require calibrated or, where nec-
essary, restrained inflammatory responses to these diverse 
insults. The development of chronic inflammatory processes, 
such as allergic airway inflammation, implies the dysregula-
tion of these normal homeostatic mechanisms.1 Macrophages 
are well known for their functional plasticity and their pleio-
tropic role in orchestrating immune responses2,3 and the al-
veolar macrophage (AM) is the resident immune cell of the 
pulmonary mucosal surface. Lung macrophages had long 
been overlooked as cellular participants in the development 
of allergic airway inflammation.4 However, recent studies 
in mouse models have revealed an important dichotomy in 
which resident AMs play largely suppressive roles,5-7 while 
recruited monocyte-derived macrophages play largely patho-
genic roles in allergic airway inflammation.5,8,9
Given their paucity as well as their relative immobility in 
the normal mammalian lung,10,11 AMs would be anticipated 
to employ paracrine means to restrain the inflammatory be-
havior of the alveolar and airway epithelial cells (ECs) which 
comprise this mucosal surface. A form of paracrine commu-
nication whose importance is increasingly appreciated in-
volves the transfer of extracellular vesicles (EVs) containing 
various molecular species of cargo from donor to recipient 
cell.12 We have identified the transcellular delivery of EVs 
containing the suppressor of cytokine signaling 3 (SOCS3) 
from AMs to ECs as a new paradigm for regulating inflam-
mation in the lung.13,14 SOCS3 serves as the endogenous 
brake on Janus kinase (JAK)-signal transducer and activator 
of transcription (STAT) signaling, which is critical in trans-
ducing the effects of numerous cytokines and growth fac-
tors.15 We have demonstrated that these AM-derived EVs are 
rapidly internalized by, and inhibit JAK-STAT signaling and 
inflammatory gene expression within, ECs.13,16
Pharmacologic inhibition of JAK is used clinically in 
rheumatoid arthritis and its potential is being widely ex-
plored in other inflammatory diseases,17 including allergic 
asthma.18-22 While SOCS3 has been suggested to promote 
type 2 immune responses by its actions in lymphocytes and 
eosinophils,23,24 its upregulation in bronchial ECs has been 
associated with anti-inflammatory actions.25,26 The import-
ant role of the epithelium as both a source of and responder 
to inflammatory mediators in allergic asthma has gained in-
creased recognition27,28 and its generation of chemokines is 
critical in the recruitment of a variety of leukocyte lineages. 
Impaired delivery of SOCS3 from AMs to ECs in the setting 
of allergic inflammation, then, could promote inflammatory 
responses. Here we show that vesicular SOCS3 secreted by 
AMs restrains allergic inflammatory responses in bronchial 
ECs in vitro, but this brake is compromised in the lungs 
of asthmatic subjects and in two mouse models of allergic 
asthma. We also demonstrate that the intrapulmonary admin-
istration of liposomes with SOCS3 as their sole cargo has 
the capacity to restrain inflammation in a mouse model of 
allergen challenge.
2 |  MATERIALS AND METHODS
2.1 | Human subjects and BALF sample 
acquisition
Subjects were men and women, ages 18-75, with or without 
mild to moderate stable asthma. Asthma diagnosis was based 
on symptoms, methacholine challenge, and/or bronchodilator 
reversibility. Stability was based on an absence of changes in 
asthma medications and no exacerbations requiring treatment 
with steroids within 30 days of bronchoscopy. Exclusion cri-
teria included a smoking history greater than 30 pack-years, 
a history of lung disease other than asthma, and other medi-
cal conditions that might increase the risks associated with 
bronchoscopy. BALF samples were acquired from a total 
of 16 subjects undergoing research-related bronchoscopies 
at the University of Michigan Hospital Medical Procedure 
Unit. BALF samples were collected and treated as protocol-
ized research specimens with a uniform instillation volume 
(180 mL). Informed consent was obtained from each subject 
prior to sample collection in accordance with the Declaration 
of Helsinki and with approval of the University of Michigan 
Institutional Review Board.
2.2 | Animals
Pathogen-free male and female C57BL/6 mice aged 6-8 
weeks were purchased from The Jackson Laboratory. The 
mice were housed in groups of 5 and they had ad libitum 
access to water and food. Mice were treated in accordance 
with relevant national and local guidelines and regulations 
regarding the use of experimental animals and with approval 
of the University of Michigan Committee for the Use and 
Care of Animals.
2.3 | Mouse models of allergic airway 
inflammation
Male (n = 10 per group) and female (n = 5 per group) mice 
were sensitized with 20 µg ovalbumin (OVA, Sigma-Aldrich, 
St. Louis, MO) mixed with 2 mg of alum (Thermo Fisher 
Scientific, Waltham, MA) in 150 µL PBS through intraperi-
toneal injection on day 0. On Days 7 and 8, mice were chal-
lenged with nebulized 1% OVA, as described previously.29 
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Control groups (males, n = 5 per group and females, n = 3 
per group) were sensitized with PBS and were challenged 
with nebulized PBS.
Male mice (n  =  5 per group) were also sensitized and 
challenged with 100 µg of Dermatophagoides pteronyssi-
nus HDM extract (Greer Laboratories) protein suspended 
in 50 µL of PBS and administered by oropharyngeal (o.p.) 
administration on Days 0, 7, and 8 as described previously.5 
Mice exposed to 50 µL of PBS on the same days served as 
controls. For both OVA and HDM models, lung lavage fluid 
was collected on Day 9. The first flush of 600 µL was stored 
separately for cytokine analysis. Additional flushes were 
performed to collect all lung cells and total numbers were 
counted. Approximately 50 000 lung cells per mouse were 
cytospun onto slides at 800 rpm for 2 minutes. The percent-
age of eosinophils and neutrophils among 300 total cells was 
determined in the cytospins by differential counting after 
H&E staining of the slides.
2.4 | Cells
A continuous SV40-transformed line of primary AMs origi-
nally obtained from lavage fluid of normal mice (MHS, 
CRL-2019),30 which we have utilized previously as a source 
of EVs,16 and a transformed human bronchial EC line 
(BEAS-2B) were purchased from American Type Culture 
Collection. Normal primary mouse AMs were obtained 
by lung lavage of a male C57BL/6 wild type mouse (The 
Jackson Laboratory) and subsequently immortalized by in-
fecting with the J2 retrovirus carrying v-raf and v-myc on-
cogenes as previously described.31 Primary AMs were also 
obtained by lavage from PBS- and allergen-challenged mice. 
AMs and AM cell lines were cultured in RPMI 1640 sup-
plemented with 10% FBS and 1% penicillin/streptomycin 
(Gibco). However, because serum itself is a source of EVs, 
AMs were cultured in serum-free RPMI 1640 medium when 
they were being used as a source of EVs.
2.5 | Isolation of EVs
Upon reaching confluency, AM medium was replaced 
with serum-free RPMI 1640 for 90 minutes (at 37°C, 5% 
CO2) and AM conditioned medium (CM) was harvested 
as a source of basally secreted EVs. Cell debris and ap-
optotic bodies were removed from CM by centrifugation 
at 4°C at 500×g and 2500×g, respectively. Two different 
methods were used to purify EVs in this study. In initial 
studies with MHS cells, EVs were pelleted from MHS 
CM by 17 000×g ultracentrifugation for 30 minutes, with 
quantification of EV numbers performed as described pre-
viously.16 During the course of our studies, we observed 
that the yield of EVs by this isolation method was limited 
due to their rupture owing to the high shear forces from 
ultracentrifugation. This prompted us to instead employ 
the gentler method of centrifugal filtration of AM CM 
through a 100 kDa exclusion filter (MilliporeSigma)32 and 
this technique was employed for EV isolation from the J2-
immortalized AM cell line. While this approach provided 
a higher yield of EVs and vesicular SOCS3, EVs isolated 
using both methods had similar properties and modulatory 
characteristics.
2.6 | In vitro challenge of BEAS-2B cells
BEAS-2B ECs were cultured in DMEM with 10% FBS and 
1% penicillin/streptomycin (Gibco) in six-well tissue-culture 
plates, and once 80% confluent, they were serum-deprived 
overnight. The next day, serum-free RPMI medium alone (2 
mL), AM CM (2 mL) or AM EVs (at a ratio of 5 EVs per EC 
in 2 mL of RPMI) was added to each well of ECs and incu-
bated for 2 hours. ECs were then washed and stimulated with 
human IL-4 + IL-13 (both 10 ng/mL, PeproTech) or HDM 
(10 μg/mL, Greer Laboratories) and harvested after 1 hours 
for analysis of transcription factor phosphorylation by west-
ern blot or harvested after 6 hours for analysis of cytokine 
mRNA by qPCR.
2.7 | Western blotting
BEAS-2B ECs were lysed and protein concentrations were 
determined by the DC protein assay (modified Lowry assay 
from Bio-Rad Laboratories). Samples containing 40-50 μg 
EC lysate protein were separated by SDS-PAGE using 8% 
gels (for phosphorylated proteins) and those containing 10 μg 
AM lysate protein or 20-30 μg AM CM (or mouse lavage fluid 
after 100 kD filtration) protein were separated on 12.5% gels 
(for SOCS3 proteins) and then transferred to nitrocellulose 
membranes. After blocking with 4% BSA, the membranes 
were probed overnight with antibodies against phospho- and 
total STAT3 (both Cell Signaling, 1:1000), phospho-STAT6 
(Cell Signaling, 1:500), β-actin (Sigma-Aldrich, 1:10 000) or 
SOCS3 (Abcam, 1:750). Films were developed using ECL 
detection (Amersham Biosciences) after incubation with 
peroxidase-conjugated secondary antibody (Cell Signaling). 
Relative band densities were determined by densitometric 
analysis using Image J software.
2.8 | RNA isolation and qPCR
BEAS-2B ECs and primary AMs were suspended in 700 μL 
of TRIzol reagent (Thermo Fischer Scientific) and RNA was 
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extracted using the RNeasy Micro Kit (Qiagen) according 
to the manufacturer’s instructions and converted to cDNA. 
Levels of mRNA were assessed by qPCR performed with 
a SYBR green kit (Applied Biosystems) on an ABI Prism 
7300 thermocycler (Applied Biosystems). Expression of eo-
taxin-1, TSLP, IL-33, IL-6, GM-CSF, inducible nitric oxide 
synthase (iNOS), and found in inflammatory zone 1 (FIZZ1, 
also termed resistin like alpha) was assessed (sequences of 
primers used can be found in Supplemental Table 1). Relative 
gene expression was determined by the ΔCT method and ei-
ther GAPDH (for ECs) or β-actin (for AMs) was used as a 
reference gene.
2.9 | Synthetic SOCS3 liposomes
To generate synthetic vesicles with SOCS3 as lone cargo 
molecule, recombinant mouse SOCS3 was cloned, ex-
pressed, and purified to homogeneity as described previ-
ously.33 Thin phospholipid films were prepared from a 1:1 
mixture of dioleoyl phosphocholine and dioleoyl phos-
phoglycerol and dried. These were mixed with PBS with 
or without recombinant SOCS3 protein (3.5 µg/mL) and 
intermittently vortexed to produce multilamellar vesicles, 
followed by serial extrusion. Resulting liposomes were 
centrifuged to remove unloaded SOCS3 protein and pellets 
suspended in PBS and stored at 4°C until use. Empty (PBS 
control) and SOCS3 liposomes both had a mean diameter 
of ~110 nm as determined by dynamic light scattering and 
comprised a single, homogenous population of liposomes, 
as determined by polydispersity index.33 U.S. Patent ap-
plication 16/071 290 describing these liposomes was filed 
on July 19, 2018.
For in vitro experiments with BEAS-2B ECs, we em-
ployed a dose of liposomes containing 10 ng of recombi-
nant SOCS3, since this approximates the amount secreted 
by 1  ×  106 primary AMs that we previously determined 
to be capable of inhibiting STAT3 activation in normal al-
veolar ECs.13 For both allergic mouse models, mice were 
treated o.p. with either synthetic empty (ie, PBS) or SOCS3 
liposomes in a volume of 30 µL PBS 2 hours prior to chal-
lenge with PBS or HDM (o.p.) or OVA (nebulization) on 
both Days 7 and 8 (see Supplemental Figure 3). The dose of 
liposomes administered in vivo contained 20 ng of recom-
binant SOCS3, as this approximates the amount secreted 
by primary AMs that we previously determined capable 
of inhibiting STAT3 activation in cytokine-treated mouse 
lungs.13
2.10 | SOCS3 and cytokine analysis in 
lavage fluids
SOCS3 was measured in cell-free human or mouse lav-
age fluid samples and in primary AM CM that both had 
been concentrated using 100 kD Amicon Ultra exclusion 
filters (MilliporeSigma). After sonication of the samples 
(Branson Sonifier 250: 40% duty cycle, output 3) to dis-
rupt EVs, SOCS3 levels were determined using a SOCS3 
ELISA kit according to the manufacturer’s instructions 
(Cloud-Clone). Cell-free mouse lavage fluids (not soni-
cated) were also used to measure levels of IL-4, IL-5, IL-6, 
KC, MCP-1, IP10, and eotaxin-1 by multiplex ELISA 
(Milliplex, MilliporeSigma) and to measure IL-33 levels 
by ELISA (R&D Systems).
2.11 | Statistical analysis
Data are presented as mean ± standard error of the mean 
(SEM). To determine the normality of the data a D’Agostino 
and Pearson omnibus normality test was used. Data were 
log-transformed to fit a normal distribution when not dis-
tributed normally. Differences between groups were tested 
using a one-way ANOVA followed by Sidak’s test for mul-
tiple comparisons, or by a Student t test, as appropriate. A 
two-way ANOVA was performed to analyze the effect of 
both treatment and sex (and their interaction) using Prism 8.0 
(GraphPad Software). P-values below .05 were considered to 
be significant.
Sex Age Smoking history ICS % predicted FEV1 ACQ score
Female 47 N No 96 0.57
Female 30 N Yes 53 2.71
Female 50 F No 93 0.71
Male 50 N Yes 97 0.42
Female 27 N No 117 0.57
Female 49 N Yes 123 0
Abbreviations: ACQ, asthma control questionnaire; ICS, inhaled corticosteroid; N, never; F, former.
T A B L E  1  Demographic and clinical 
characteristics of asthmatic subjects
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3 |  RESULTS
3.1 | Reduced levels of AM-derived SOCS3 
in BALF of subjects with asthma and mice in 
two models of allergic inflammation
We have previously shown that constitutive AM secretion 
of vesicular SOCS3 can be bidirectionally modulated in 
various acute and chronic inflammatory environments.14,33 
Since asthma likewise represents an inflammatory envi-
ronment in which AMs are known to be dysregulated,9,34 
we hypothesized that AM secretion of this natural brake 
on JAK-STAT signaling within the lung might be im-
paired. BALF was collected from the lungs of both asth-
matic (n = 6; Table 1) and non-asthmatic control (n = 10; 
Table 2) subjects and subjected to sequential centrifugation 
and sonication steps before analysis via ELISA (Figure1A). 
Asthmatic subject BALF demonstrated significantly lower 
levels of secreted SOCS3 than that of normal controls 
(Figure 1B).
We next evaluated SOCS3 secretion in two mouse models 
of acute allergic inflammation. Mice were sensitized (day 0) 
and challenged (Days 7 and 8) with either PBS, HDM, or 
OVA, and lavage fluid was collected on Day 9. We have pre-
viously reported that both of these protocols cause leukocyte 
influx and cytokine generation in the lungs.5,35 As compared 
to control challenge with PBS, both allergen challenge mod-
els exhibited decreases in SOCS3 protein levels contained 
in either neat BALF subjected to sonication (Figure 1C,D) 
or in EVs purified from BALF (Figure 1E). AMs retrieved 
from allergen-challenged mice exhibited no difference in 
intracellular SOCS3 relative to cells from PBS-challenged 
control mice (Supplemental Figure 1A). However, AMs from 
allergen-challenged mice secreted significantly less SOCS3 
into CM in vitro (Figure 1F) despite elaborating more EVs 
(Supplemental Figure 1B) than AMs from PBS-challenged 
mice. Thus, the ratio of SOCS3 per EV elaborated was 
clearly reduced in CM from AMs of challenged mice. These 
data indicate that homeostatic secretion of SOCS3 by AMs 
is impaired in animal models of allergic asthma, as it is in 
human asthma.
3.2 | Mediators implicated in asthma 
decrease AM SOCS3 secretion in vitro
The decreases in the vesicular SOCS3 secretion observed in 
asthmatics and allergen-challenged mice could reflect modu-
lation by inflammatory mediators present in the lungs. To 
explore this possibility, we studied the effects of exogenous 
addition of the type 2 cytokine IL-4 as well as the EC-derived 
type 2-promoting cytokines IL-33, TSLP, and IL-25 on in 
vitro AM SOCS3 expression and secretion. For comparison, 
we also examined the effect of the anti-inflammatory glu-
cocorticoid dexamethasone. J2-immortalized primary mouse 
AMs incubated for 48 hours with IL-4, IL-33, or TSLP exhib-
ited significantly lower SOCS3 protein secretion (Figure 2A) 
in association with a possible reduction in intracellular ex-
pression (Figure 2B); qualitatively similar effects of IL-25 
did not reach statistical significance. In contrast, incubation 
with dexamethasone significantly increased basal SOCS3 se-
cretion without increasing intracellular levels (Figure 2A,B). 
These data suggest that inflammatory cytokines are capable 
of inhibiting SOCS3 secretion by AMs, and this may con-
tribute to the observed defects in asthmatics and allergen-
challenged mice.
3.3 | IL4 and IL-33 treatment of AMs 
abrogates the ability of AM-derived CM and 
EVs to inhibit bronchial EC signaling and 
mediator gene expression
Previously we reported that SOCS3 protein secreted within 
AM-derived EVs has the ability to inhibit JAK-STAT 
signaling and expression of its downstream inflammatory 
genes in alveolar ECs.13 We tested whether these findings 
extend to bronchial ECs by the BEAS-2B human bronchial 
EC line, and to stimuli relevant to allergic airway inflam-
mation, namely the type 2 cytolines IL-4/IL-13 and HDM. 
Both CM and EVs (added at a typically employed ratio of 
5 EVs:1 EC) constitutively elaborated by AMs inhibited 
bronchial EC STAT3 activation in response to IL-4/IL-13 
and HDM (Supplemental Figure 2A; Figure 3A), while only 
EVs significantly inhibited STAT6 activation in response 
to IL-4/IL-13 (Supplemental Figure 2B; Figure  3B). CM 
and EVs also inhibited BEAS-2B expression of eotaxin-1 
(Supplemental Figure 2C; Figure 3C), IL-33 (Supplemental 
Figure 2E; Figure 3E), GM-CSF (Supplemental Figure 2F; 
Figure 3F), and IL-6 (Supplemental Figure 2G; Figure 3G) 
induced by IL-4/IL-13 and/or HDM. TSLP expression in 
BEAS-2B cells was only significantly induced by HDM 
stimulation, and pretreatment with either CM or EVs pre-
vented this induction (Supplemental Figure 2D; Figure 3D). 
These data demonstrate that EVs derived from resting AMs 
and known to contain SOCS3 are capable of inhibiting 
T A B L E  2  Control subject demographics
Sample size (n): 10
Median age 52 years
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signaling and gene expression responses of bronchial ECs 
pertinent to allergic inflammation.
Next, we asked whether pretreatment of AMs with IL-4, 
IL-33, or dexamethasone––which altered EV SOCS3 lev-
els––influenced the ability of their secreted EVs to inhibit 
IL-4/IL-13-induced JAK-STAT signaling in BEAS-2B 
cells. EVs from dexamethasone-pretreated AMs, containing 
higher SOCS3 levels than basal AMs, retained the inhibitory 
effect on IL-4/IL-13-induced STAT3 signaling (Figure 4A). 
In contrast, EVs from IL-4-pretreated AMs exhibited no in-
hibitory effect, while those from IL-33-pretreated AMs actu-
ally augmented STAT3 and STAT6 activation in response to 
IL-4/IL-13 (Figure 4A,B). These data suggest that impaired 
secretion of AM SOCS3 in the context of allergic inflam-
mation may result in a failure to restrain STAT-induced 
inflammation.
F I G U R E  1  SOCS3 secretion by AMs is reduced in the lungs of asthmatic subjects and allergen-challenged mice. (A) Schematic depiction of 
human subject BALF processing for SOCS3 ELISA. SOCS3 protein levels in sonicated lavage BALF of both normal and asthmatic subjects (B), 
HDM-challenged mice (C), and OVA-challenged mice (D). SOCS3 protein levels in the vesicular fraction of BALF of OVA-challenged mice (E) 
and in the vesicular fraction of CM isolated from AMs of OVA-challenged mice. For (C), (D), and (E), SOCS3 was quantitated in samples obtained 
24 hours after the second of two consecutive daily intrapulmonary allergen challenges. SOCS3 was determined by western blot in (C) and by 
ELISA in all other panels. Each point represents an individual subject or mouse, and the mean ± SEM from each group is shown. *P < .05, using a 
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3.4 | Synthetic SOCS3 liposomes 
inhibit bronchial EC signaling and 
mediator expression
Natural AM-derived EVs contain a myriad of other cargo 
molecules besides SOCS3. In order to determine if SOCS3 
itself was sufficient to attenuate bronchial EC signaling, 
we generated synthetic phospholipid vesicles in which re-
combinant SOCS3 was the lone cargo molecule, and tested 
their effects on EC inflammatory responses in vitro. We 
previously determined that 10 ng of liposomal recombi-
nant SOCS3 protein yielded a degree of STAT3 inhibition 
bioequivalent to that contained in natural AM EVs from 
1  ×  106 cells.33 As compared to empty liposomes loaded 
with PBS alone, SOCS3 liposomes inhibited EC activation 
of both STAT3 (Figure 5A) and STAT6 (Figure 5B) in re-
sponse to IL-4/13. SOCS3 liposomes also inhibited gene 
expression of eotaxin-1 (Figure 5C), TSLP (Figure 5D) and 
IL-33 (Figure 5E) elicited by stimulation with both IL-4/13 
and HDM. Thus, these synthetic SOCS3 liposomes exert 
similar anti-inflammatory actions on bronchial ECs as do 
natural AM EVs.
3.5 | Synthetic SOCS3 liposomes 
attenuate the development of allergic airway 
inflammation
The impaired in vivo secretion of AM-derived SOCS3 avail-
able for delivery to ECs in the setting of allergic inflamma-
tion (Figure 1) would be expected to disrupt homeostasis 
and thereby favor inflammatory responses. Since synthetic 
SOCS3 liposomes proved to be effective in vitro, we sought 
to test whether they could be used to rescue the endogenous 
SOCS3 secretory defect in an allergic model of airway in-
flammation in vivo. Therefore, both male (both PBS groups: 
n = 5; both OVA groups: n = 10) and female mice (PBS: 
n = 3; OVA: n = 5) were treated o.p. with either empty or 
SOCS3 liposomes 2 hours prior to challenge with PBS or 
OVA (aerosolized) on both Days 7 and 8 (Supplemental 
Figure 3); we employed a dose of 20 ng of liposomal 
SOCS3 per mouse, a dose determined to be bioequivalent 
to that contained in natural AM EVs which was capable 
of inhibiting STAT activation in cytokine-treated lungs in 
vivo.13 PBS challenge elicited no inflammatory response 
and neither empty nor SOCS3 liposomes had any effects in 
PBS-challenged mice (not shown). Increased total cells, eo-
sinophils, and neutrophils were detected in lavage fluid of 
OVA-challenged mice treated with empty liposomes as com-
pared to PBS challenged mice treated with empty liposomes 
(Supplemental Figure 4A; Figure 6A,B). As previously 
reported,36,37 OVA-challenged female mice had significantly 
higher eosinophil numbers than their male counterparts 
(Figure 6A). SOCS3 liposome treatment reduced the number 
of total cells, eosinophils, and neutrophils in BALF in OVA-
challenged mice as compared to empty liposome treatment 
(Supplemental Figure 4A; Figure 6A,B). No differences 
were observed in total AM numbers in BALF (Supplemental 
Figure 4B). SOCS3 liposome treatment affected numbers of 
total cells, eosinophils and neutrophils similarly in OVA-
challenged males and females (Supplemental Figure 4A; 
Figures 6A,B).
Lavage fluid of empty liposome-treated and OVA-
challenged mice exhibited elevated levels of inflammatory 
cytokines (IL-4, IL-5, IL-6, and IL-33) and chemokines 
(KC, MCP-1, and IP10) (Figure 6C-I). As compared to 
F I G U R E  2  SOCS3 secretion and expression is reduced in AMs exposed to inflammatory cytokines. (Top) Relative SOCS3 protein levels 
determined by western blot in (A) vesicular fraction of CM, and in (B) lysates from AM cell line exposed for 48 hours to IL-4 (10 ng/mL), IL-33 
(20 ng/mL), TSLP (50 ng/mL), IL-25 (100 ng/mL) or dexamethasone (DEX, 1 μM). (Bottom) Representative SOCS3 WBs from vesicular fraction 
of CM (A) and cell lysates (B). Dashed line represents non-contiguous lanes from two separate blots. #P < .05 as compared to unstimulated control, 
using a one-way ANOVA followed by Sidak’s multiple comparisons test 
(A) (B)
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F I G U R E  3  AM-derived EVs inhibit STAT3 and STAT6 activation as well as inflammatory gene expression in challenged bronchial ECs. 
(A) (Top) Representative WBs; (Bottom) Activation of STAT3 (phosphorylated as the percentage of total STAT3), and (B) (Top) Representative 
WBs; (Bottom) activation of STAT6 (phosphorylated as the percentage of β-actin)––both determined by densitometry––in BEAS-2B ECs 
pretreated with or without AM EVs (EV:cell ratio 5:1) and thereafter stimulated with IL-4/IL-13 (10 ng/mL each) or HDM (10 μg/mL) for 1 hours. 
Data represent mean ± SEM from 3 to 5 independent experiments. Dashed line represents non-contiguous lanes from the same blot. Relative 
expression of (C) eotaxin-1, (D) TSLP, (E) IL-33, (F) GM-CSF and (G) IL-6 mRNA in BEAS-2B ECs pretreated with or without AM EVs and 
thereafter stimulated with IL-4/IL-13 (10 ng/mL each) or HDM (10 μg/mL) for 6 hours. All data represent fold change relative to untreated control, 
and are mean ± SEM from 5 to 6 independent experiments. #P < .05 as compared to non-pretreated control ECs. *P < .05 as compared to non-EV-
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treatment with empty liposomes, SOCS3 liposome treat-
ment in OVA-challenged mice reduced the levels of IL-4, 
IL-6, KC, MCP-1, IP10 (Figure 6C,E-H), and IL-33 
(Figure 6I). As was also true for eosinophil numbers, we 
observed higher levels of IL-6, IL-5, MCP-1, and IP10 in 
OVA-challenged females as compared to males (Figure 
6D,E,G,H). For most of these cytokines/chemokines, the 
magnitude of the inhibitory effect of SOCS3 liposome 
treatment was similar in both sexes; however, SOCS3 li-
posomes lowered MCP-1 levels more in OVA-challenged 
females than in OVA-challenged males (Figure 6G). These 
data demonstrate that intrapulmonary treatment with 
SOCS3 liposomes abrogates both the cellular and molecu-
lar components of allergic inflammation.
3.6 | Synthetic SOCS3 liposomes attenuate 
macrophage polarization during allergic 
airway inflammation
BALF cells from empty and SOCS3 liposome-treated PBS 
and OVA-challenged mice were pooled and plated, and 
those remaining adherent following 18-hours culture were 
predominantly macrophages. By qPCR analysis, cells from 
OVA-challenged mice that had been treated with empty li-
posomes showed substantial upregulation of mRNA for 
the M1 marker inducible nitric oxide synthase (iNOS) 
(Figure 7A) and the M2 markers FIZZ1, YM1 and IRF4 rela-
tive to that observed following PBS challenge (Figure 7D-F). 
As compared to empty liposome treatment, SOCS3 liposome 
F I G U R E  4  EVs from cytokine-
pretreated AMs lose their capacity to 
inhibit STAT activation in response to 
inflammatory stimuli. A, (Top) Activation 
of STAT3 (as percentage of total STAT3) 
(Bottom) representative WBs, and B, (Top) 
activation of STAT6 (as percentage of 
β-actin) (Bottom) representative WBs––both 
determined by densitometry––in BEAS-2B 
ECs pretreated with EVs from AM cell line 
exposed for 48 hours to either IL-4, IL-33 or 
DEX, and thereafter stimulated with IL-4/
IL-13 (10 ng/mL each) for 1 hours. Dashed 
line represents non-contiguous lanes from 
two separate blots. All data are mean ± 
SEM from 5 to 6 independent experiments. 
#P < .05 vs untreated cells; *P < .05, using 
a one-way ANOVA followed by Sidak’s 
multiple comparisons test 
(A)
(B)
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administration to OVA-challenged mice attenuated ex vivo 
macrophage expression of M1 markers iNOS, TLR4, and 
IRF5 (Figure 7A-C) as well as M2 markers FIZZ1, YM1 and 
IRF5 (Figure 7D-F). These data indicate that while M2 po-
larization predominates in OVA-sensitized and challenged 
mice, treatment with SOCS3 liposomes is able to inhibit 
macrophage polarization to both M1 and M2 phenotypes, 
as reflected by reduced expression of cell surface markers 
(iNOS, TLR4, FIZZ1, and YM1) as well as of key responsi-
ble transcription factors (IRF4 and IRF5).
4 |  DISCUSSION
Here we interrogated the role of anti-inflammatory SOCS3, 
secreted within EVs by AMs, in allergic inflammatory re-
sponses in the airways. Our key findings were that: (i) basal 
SOCS3 secretion in the lung is impaired in both asthmatics 
and in mouse models of allergic asthma; (ii) AM-derived 
SOCS3 dampens bronchial EC inflammatory responses in 
vitro; and (iii) intrapulmonary administration of liposomal 
recombinant SOCS3 can rescue the secretory defect in mice 
and exert broad suppression of diverse inflammatory path-
ways and events.
The complex interplay between multiple cell types during 
airway inflammation in response to allergens remains incom-
pletely defined. However, due to their location in the airway 
and close proximity to each other, bronchial ECs and AMs are 
the first lines of contact for inhaled allergens. Their coopera-
tion is essential for proper inflammatory responses and main-
tenance of homeostasis and as the resident immune cell of the 
pulmonary mucosal surface, AMs are in the perfect position to 
orchestrate these responses. We previously demonstrated that 
constitutive secretion of vesicular SOCS3 by AMs could be 
further potentiated in response to a “request signal” received 
from ECs in order to dampen their inflammatory response 
during infection.14 Data presented herein show that during 
acute allergic airway inflammation, AMs are unable to answer 
such a request, and their impaired secretion of endogenous 
SOCS3 would be expected to facilitate airway inflammation.
We acknowledge two limitations of this study. First, we 
have not directly studied the inflammation-modulatory 
F I G U R E  5  Synthetic liposomes containing recombinant SOCS3 inhibit STAT activation and inflammatory cytokine production by BEAS-
2B cells. (A) Activation of STAT3 (phosphorylated as percentage of total STAT3) and (B) activation of STAT6 (phosphorylated as percentage of 
β-actin)––both determined by WB––in BEAS-2B ECs pretreated with empty or SOCS3 liposomes and thereafter stimulated with or without IL-4/
IL-13 (10 ng/mL each) for 1 hours. Relative expression of (C) eotaxin-1, (D) TSLP, and (E) IL-33 mRNA in BEAS-2B ECs pretreated with empty 
or SOCS3 liposomes and thereafter stimulated with IL-4/IL-13 (10 ng/mL each) or HDM (10 μg/mL) for 6 h; data are presented as fold change 
relative to untreated control. Data are from 5 independent experiments. #P < .05 as compared to control untreated ECs. *P < .05, using a one-way 
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actions of EVs derived from human AMs, but instead draw 
inferences from the actions of EVs elaborated by mouse AM 
cell lines. This reflects the logistical realities of ready ac-
cess to large numbers of mouse AMs from which EVs can 
be isolated, as opposed to the limited access to AMs from 
asthmatic and control humans. However, we have previously 
confirmed that AMs from human subjects do, indeed, secrete 
SOCS3 ex vivo,13 and would, therefore, anticipate similar an-
ti-inflammatory potential. Second, we have not definitively 
determined that SOCS3 secreted onto the mucosal surface 
in vivo and recovered in BALF from normal humans or mice 
derives exclusively from resident AMs. However, we have 
previously reported13,14 that in contrast to the abundant ca-
pacity of AMs to secrete SOCS3, that exhibited by a variety 
of other cell types (alveolar ECs, neutrophils, monocytes, 
lung fibroblasts, and certain other macrophage populations) 
is minimal. While we anticipate that resident AMs are the 
predominant source of secreted SOCS3 in vivo, we cannot 
exclude contributions from other cell types.
In our studies, we observed that AMs secreted less SOCS3 
during acute allergic airway inflammation and we sought to 
gain some insight into the responsible mechanism(s) using 
F I G U R E  6  Intrapulmonary administration of synthetic liposomes containing recombinant SOCS3 inhibits eosinophil and neutrophil 
recruitment and inflammatory cytokine generation in the allergen-challenged lung in vivo. (A) Eosinophil numbers and (B) neutrophil numbers 
in lavage fluid of OVA-challenged male (green) and female (purple) mice determined 24 hours after the second of two consecutive daily 
intrapulmonary PBS or OVA challenges. Protein levels of (C) IL-4, (D) IL-6, (E) IL-5, (F) KC, (G) MCP-1, (H) IP10, and (I) IL-33 in lavage fluid 
of PBS- and OVA-challenged male (green) and female (purple) mice determined 24 hours after the second of two consecutive daily intrapulmonary 
PBS or OVA challenges. Empty (PBS) or SOCS3 liposomes were administered o.p. 2 hours before challenges on both days. *P < .05, using a two-
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both our in vitro and in vivo models. In vitro exposure of 
the AM cell line to IL-4, IL-33 or TSLP––mediators showed 
to be increased in the milieu of the inflamed lung––reduced 
intracellular SOCS3 protein levels as compared to those ob-
served in untreated AMs. This approach, albeit reductionist 
in nature, suggests that the decrease in SOCS3 secretion by 
AMs could reflect less intracellular SOCS3 protein available 
for packaging into EVs, perhaps because of interference with 
transcription/translation of the protein during inflammation. 
In contrast, in the in vivo HDM model, SOCS3 secretion by 
AMs was diminished despite these cells exhibiting similar 
intracellular SOCS3 protein levels and elaborating more total 
EVs as compared to AMs from PBS-challenged mice. These 
data suggest that reduced SOCS3 secretion was attributable 
instead to lower amounts of SOCS3 protein incorporated per 
secreted EV. Taken together, our data suggest that while in-
flammatory cytokines have the potential to reduce SOCS3 
secretion by suppressing the intracellular expression of the 
protein, the predominant operative mechanism in vivo may 
instead involve defective packaging of intracellular SOCS3 
within EVs. Indeed, there is precedent for the amount of 
SOCS3 protein packaged per EV to be directly modulated 
independent of bulk intracellular levels.13 Further work is 
needed to definitively elucidate the molecular mechanisms 
responsible for diminished SOCS3 secretion within AM EVs 
in the setting of allergic inflammation.
We previously reported that various pro- and anti-inflam-
matory signaling molecules could bidirectionally regulate 
AM secretion of SOCS3.13 Additionally, we demonstrated 
that innate immune activation and/or type I inflammation (ie, 
acute bacterial and viral infections) results in a significant in-
crease in SOCS3 secretion in the lungs of naïve mice.14 These 
current data extend the phenomenon of dynamic regulation 
of AM SOCS3 secretion to substances important in modu-
lating type 2 inflammatory responses. Although the precise 
quantitative relationship between SOCS3 content and anti-in-
flammatory actions of EVs remains to be clarified, our data 
do point to a qualitative relationship in that EVs from AMs 
treated with type 2-associated cytokines such as IL-4, IL-13, 
and TSLP––exhibiting reduced SOCS3––exhibited a parallel 
loss of their anti-inflammatory actions on ECs in vitro. We 
would anticipate that a similar loss of anti-inflammatory ac-
tivity would accompany the reduced SOCS3 content of EVs 
elaborated by AMs from allergen-challenged mice in vivo. 
Unfortunately, this possibility could not be feasibly tested di-
rectly because the numbers of EVs that can be obtained from 
AMs isolated from these mice are limiting. However, the fact 
that supplementation of SOCS3 protein via synthetic lipo-
somes resulted in reduced inflammatory cytokine production 
and cell recruitment in allergic mice indirectly suggests that 
loss of AM SOCS3 secretion facilitates enhanced allergic 
inflammation.
F I G U R E  7  Intrapulmonary administration of synthetic liposomes containing recombinant SOCS3 inhibits AM polarization. mRNA 
expression of M1 markers (A) iNOS, (B), TLR4, (C) IRF5 and M2 markers (D) FIZZ1, (E) YM1, and (F) IRF4 in AMs isolated from lavage 
fluid of PBS- and OVA-challenged mice pretreated with empty liposomes or SOCS3 liposomes. *P < .05, using a one-way ANOVA followed by 
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A variety of signaling pathways and transcription factors 
(such as STAT1, STAT3, and STAT6) upregulated or acti-
vated in the airway epithelium have been shown to be im-
portant in mediating airway responses to allergens in both 
mouse models and in asthmatics.38-40 Our current studies 
demonstrate that endogenously released AM-derived EVs 
containing SOCS3 are capable of inhibiting the activation of 
both STAT3 and STAT6, indicating a broad anti-inflamma-
tory repertoire. Importantly, we found that this homeostatic 
control mechanism is disrupted during allergic inflammation, 
prompting an opportunity for therapeutic rescue. Attempting 
to accomplish this with natural AM-derived EVs is potentially 
problematic. First, the presence of myriad cargo molecules 
other than SOCS3 in natural EVs could confound therapeutic 
studies. Second, the prospect of treatment with natural EVs 
poses a variety of immunologic, logistical, and regulatory 
challenges. To circumvent these limitations, we engineered 
synthetic phospholipid-based liposomes whose only cargo is 
recombinant SOCS3. Our findings indicate that these lipo-
somes possess anti-inflammatory actions when delivered to 
either bronchial ECs in vitro or by intrapulmonary adminis-
tration in mouse models of allergic inflammation. They inhib-
ited the activation of STAT3 and STAT6 in bronchial ECs. In 
vivo, they inhibited inflammatory cell influx, the expression 
of a wide range of cytokines and chemokines, as well as in-
hibition of AM polarization to both M1 and M2 phenotypes; 
the latter is important because polarized macrophages are key 
drivers of inflammatory responses.41,42 Homogeneous lipo-
somes of uniform phospholipid and SOCS3 cargo content and 
size could be readily synthesized to a large scale. Moreover, 
synthetic SOCS3 liposomes appear to target a broader range 
of inflammatory signaling pathways than do pharmacologic 
inhibitors of JAK. These features endow SOCS3 liposomes 
with the potential to comprise an innovative anti-inflamma-
tory approach for the treatment of asthma.
In conclusion, we have identified the constitutive se-
cretion of SOCS3 within EVs as one potential mechanism 
by which resident AMs restrain allergic inflammatory re-
sponses in the airways. Vesicular SOCS3 exerts broad 
inhibitory effects on various aspects of inflammatory sig-
naling and responses within airway ECs. AM incorporation 
of SOCS3 protein within EVs is known to be a regulatable 
phenomenon and we demonstrate here that this process can 
be reduced by type 2 cytokines in vitro and during allergic 
inflammation in vivo. We speculate that the impairment of 
this homeostatic anti-inflammatory brake promotes the de-
velopment and persistence of airway inflammation. Its res-
toration by intrapulmonary administration of SOCS3 within 
synthetic vesicles can attenuate inflammation. Future studies 
will be required to evaluate the importance of this defect in 
SOCS3 secretion and the therapeutic potential of synthetic 
SOCS3 liposomes in more chronic models of allergic airway 
inflammation.
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